MOMO NEWS/Whatever

[gmarc66]

there was an 8-k issued mid afternoon yesterday on GNDV...all gibberish to me thouhg....anyone have any comments on it.

thanks..giulia

Also, ERHE is movign premarket...not sure why...keep eye on it

[wrangler]

Hi handyman
I've got shares in BIGN . Been wondering why there hasn't been any price movement with all the positive news coming out. I thought for sure there would be good price movement from recent news that I'll post to. Volume is increasing but that's all. Don't know what to think about it with such volume increase ,why not price increase. Why would anybody want to sell at such a low price if the news is expected to be positive reaction from investors.

Press Release Source: Biogenerics Limited
Biogenerics Ltd. Announces Spin-Off of Tyche Energy Division and Stock Gift
Friday December 9, 4:31 pm ET

TORONTO, Dec. 9, 2005 (PRIMEZONE) -- Biogenerics Limited (Other OTC:BIGN.PK - News) and Tyche Energy, Inc., jointly announced today their plans to spin-off Biogenerics' subsidiary company, Tyche Energy, Inc.

In a special meeting held today, the board of directors of Biogenerics unanimously passed a resolution to issue and gift up to 10% of the outstanding common shares of Tyche to shareholders of Biogenerics Limited.

Biogenerics shareholders of record as of the close of business on Tuesday, December 20, 2005 will qualify for the pro rata gift of Tyche Energy shares. Biogenerics' board of directors plan to hold a subsequent meeting to finalize the gift date, and confirm the number of shares to be gifted per each share of Biogenerics stock held as of the record date.

Tyche Energy, which Biogenerics currently holds an ownership position of 37.5%, is a London, Ontario based oil and gas P & E company operating exploration projects in and around the Appalachian Basin of Ontario, Canada. Tyche Energy is developing its nearly 20,000 acre portfolio of varying working interest property rights in conjunction with several partner companies including Veteran Resources, Inc., and Talisman Energy, Inc., (TLM) presently an $18.5 billion market cap company trading on the New York Stock Exchange.

In addition to its present and scheduled exploration projects, Tyche Energy recently signed a Memorandum of Understanding (MOU) with Productive Geoscience to add a state-of-the-art seismic petroleum resource detection technology named N2Vision to its service portfolio.

About Biogenerics Limited

Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics also has joint venture activities with Tyche Energy, Hydroslotter Corporation and WW Energy Inc.

:

[setravis]

Check out EMRG........

http://www.3stocksonfire.org/trading/index.php?topic=635.new#new

[setravis]

Check out ARTX....Double Bottom

http://www.3stocksonfire.org/trading/index.php?topic=211.new#new

[wrangler]

Thursday, December 15, 2005 
Wall Street News Alert Does Not Send Fax! See The Paragragh Under "Market Commentary".
Wall Street News Alert's  for
Thursday, December 15, 2005.

BREAKING NEWS: OCEAN WEST HOLDING SIGNS DEAL WITH AVIS RENT A CAR SYSTEM TO SUPPLY AVIS' TOP 100 DOMESTIC LOCATIONS WITH ASKMENOW SERVICE! Avis customers may simply call a toll free number or text any question from their mobile phone and receive the requested information in moments. Michael Caron, VP product development for Cendant Car Rental Group, parent of Avis stated, "Avis is the first to offer this groundbreaking service to its car renters."

As a special to Wall Street News Alert Visitors, Sign up now and receive 60 days of unlimited AskMeNow for FREE. Just register HERE and enter promotion code EM11. Hurry! You must use this promotion code within the next 10 days to receive your free trial!

AskMeNow, a wholly owned subsidiary of Ocean West Holding Corporation, is the easiest, most convenient way to access information on the Internet from your cell phone or mobile device. The first mobile lifestyle network, AskMeNow allows subscribers to simply call or text message any question from a mobile telephone to receive the information requested in moments. Basic questions are answered for free, while AskMeAnything questions are answered for a small automated fee. The Company generates revenue through one-to-one advertising and sponsorship on its service, as well as per usage charges for its AskMeAnything feature. Utilizing patent-pending technology, AskMeNow launched in beta in 2004. The Company is based in Irvine, CA.

[setravis]

Did these run across anyone's radar today ?
Placed on my watch list.To see reaction in the coming days,or next year....
************************************************************
DIASYS CORP (AMEX:DYX) Change:  0.36 (+257.14%)
Last Trade: 0.50
Volume: 918,300
Avg Vol (3m): 31,389.2

News out with this one, Link :  http://biz.yahoo.com/bw/051219/20051219005736.html?.v=1 

DiaSys Corporation Announces $11.75 Million Order in Mexico for the Company's Parasitology Products
Business Wire (Mon 1:52pm) 

*************************************************************
VERIDICOM INTL INC (OTC BB:VRDI.OB) Change:  0.145 (+362.50%)
  Last Trade: 0.185
  Volume: 4,913,077
Avg Vol (3m): 109,818

Can't find any recent news, don't know what caused the big move !
*************************************************************

[gmarc66]

Hey Setravis...

VRDI I heard thur the grapevine was a group play.

could, continue tomorrow, but I would play this a quick in and out daytrade, if you chose to jump in.

goodluck to anyone who got in..i almost got in on the rebound, but, waited for a bigger dip near the eod...but, didn't go to .10 like i was hoping. 

hope someone got make some on this...got to be daring.

julia

[wrangler]

AP
Dynavax Hepatitis Vaccine Shows Promise
Monday December 19, 9:09 am ET  
Dynavax Technologies Says Vaccine for Hepatitis B Virus Passed Mid-Stage Trial

BERKELEY, Calif. (AP) -- Dynavax Technologies Corp., a biopharmaceutical focused on treatments for allergies, infectious and chronic inflammatory diseases, said Monday a mid-stage trial of its hepatitis B virus, or HBV, vaccine was successful, warranting further testing.

The drug, Heplisav, fared well in a comparative test versus GlaxoSmithKline's Engerix-B vaccine. Dynavax's President and Chief Executive Dino Dina said the drug maker wants to market Heplisav to high-risk patients unable to access conventional vaccines.

The initial focus is on patients with chronic renal failure who are about to or are already undergoing hemodialysis and are at "substantial risk" for an HBV infection as well as those who are HIV positive or have hepatitis C infection for whom a co-infection with HBV is a serious possibility.

Dynavax initiated the first of two Phase 3 clinical trials in June with 400 participants in Singapore, Korea, the Philippines, and Taiwan. The Phase 2/3 trial was conducted on participants aged 40 to 70 years, a population that experiences a lower success rate with conventional vaccines.

A second Phase 3 trial will begin in the first half of 2006.

Berkeley-based Dynavax initiated in October a Phase 1 trial in pre-dialysis patients in the United States and said it plans to conduct additional trials in selected high-risk populations.

Dynavax shares rose 3 percent, adding on 14 cents to $4.25 in pre-market trading.





 

[gnlbigte]

Check out the MOTG momo today

Modern Technology Corp Acquires INmarketing Group Adding a Projected $11,500,000 to 2005 Revenues
Tuesday December 20, 3:58 pm ET


OXFORD, MS--(MARKET WIRE)--Dec 20, 2005 -- Modern Technology Corp (OTC BB:MOTG.OB - News), a diversified technology development and acquisition company announced today it has acquired 51% of INmarketing Group, Inc. This new subsidiary adds an estimated $11.5 Million in 2005 revenues and a projected additional $14 Million in revenues for 2006. INmarketing Group generated $8.7 Million in revenues in 2004 and generated $5.8 Million in revenues in the first half of 2005.

Anthony Welch, Modern Technology Corp's Chairman said, "As promised to stockholders in prior updates, we now deliver. This is a superb addition to our portfolio and complements our strategy of continuous growth."

David J. Weiss and Andrew Perlmutter, Founders of INmarketing Group said, "We look forward to working with Modern Technology Corp and its family of companies to provide our loyal clients both the technological and pricing advantage they deserve. By expanding our distribution and integrating our systems, we will create new value and continue leading the Online Incentive Industry."

About Modern Technology Corp

Founded in 1982, Modern Technology Corp is a diversified technology development and acquisition company, building revenues by strategic acquisition and commercialization of nascent commercial technology and by the acquisition of synergistic operating companies. MOTG commercializes technology and provides to its subsidiaries new product lines, operations infrastructure, and significant intellectual capital. The company's mission is to consistently build shareholder value through accretive acquisitions of emerging technology or acquiring operating companies capable of benefiting from technology infrastructure enhancements or new product lines. For more information, visit: http://www.moderntechnologycorp.com.

[wrangler]

Aastrom Biosciences Reports Positive Human Jaw Bone Reconstruction Results from Feasibility Clinical Trial
Related Stocks   
ASTM


-- Results Indicate Company's Tissue Repair Cell Product Safely Builds New Bone for Dental Implants --

ANN ARBOR, Mich., Dec. 21 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (ASTM - news) announced today the interim results from its feasibility clinical trial conducted with the Teknon Hospital Maxillofacial Clinic in Barcelona, Spain, to evaluate the use of Aastrom's Tissue Repair Cells (TRCs) for maxillary (upper jaw) bone reconstruction in 5 patients, completed to support placement of dental implants. The study results showed clinical safety, and that the TRC treatment sites all exhibited bone growth that was statistically significant and had the desired initial integration with preexisting bone. An internal report of the clinical study, which provides more detailed information, is being filed today on Form 8-K with the SEC. This report may also be accessed on Aastrom's website using the link: http://www.aastrom.com/pdf/Jaw_Barcelona-051220.pdf.

The goal of this proof of concept, internally controlled clinical trial was to evaluate the safety and ability of TRCs -- a proprietary autologous bone marrow-derived stem cell product -- to increase bone height in the posterior maxilla (upper jaw) of 5 patients, who had severe bone loss in the region and minimal residual bone remaining. The patients were judged to have a poor prognosis with previously lost teeth due to periodontal disease and tooth decay, and additional risk factors that are known to compromise bone regeneration and preservation. These risk factors included many years of smoking, osteoporosis and advanced age. The intent of the TRC therapy was to help rebuild healthy bone so that there was enough bone to accommodate the length of the dental implants. A standard bone graft technique was used as an internal concurrent control on the other side of the maxilla.

All of the primary outcomes described by the trial protocol were successfully achieved. Results showed that all 5 patients treated locally with Aastrom's TRCs, exhibited a statistically significant increase in bone height at the 3-month evaluation point, and the cell graft had started to integrate with the surrounding preexisting bone of the upper jaw by 4 months, with no cell-related adverse events. The results were obtained from radiographs, and from biopsies taken at the interface of the original bone and the new tissue. All patients went on to receive 3-4 dental implants on each side of their maxilla.

The study employed an internal concurrent control, in which the patients were treated on one side of the maxilla with the TRC test treatment added to a standard of care procedure, and on the other side with the control standard of care procedure, a mixture of platelet-poor plasma and commercial bone mineral matrix. There was a statistically significant difference in bone formation and quality between test and control sides. Bone height in the grafted area and integration of graft into surrounding bone were increased in the TRC test maxilla, when compared with control sites receiving standard of care treatment. Post-operative bruising and swelling observed at some (3/5) of the control sites, were not observed in the TRC treated maxillae (0/5). This is the second clinical bone graft trial to report that surgical sites treated with TRCs appear to exhibit less inflammation or swelling than sites treated without TRCs.

"Edentulous patients who have lost this much jaw bone can be very difficult to treat," commented Dr. Federico Hernandez-Alfaro, Principal Investigator for the trial. "TRCs may offer an improved treatment over existing therapies because they appear to naturally accelerate integration of new bone with the existing bone in the patient, and increase bone mass for implant placement."

"Results such as these provide increasing evidence that TRCs can be safely used to regenerate bone in humans whose ability to maintain and repair their skeleton is impaired by disease or trauma," stated Janet M. Hock, B.D.S., Ph.D., Vice President Global Research and Chief Scientific Officer of Aastrom. "These early clinical studies explore tissue healing and regeneration in patients with compromised conditions, and teach us what to expect from stem cell therapy, and how to optimize the use of TRCs in clinical situations."

Aastrom is implementing a "proof of concept" clinical plan to evaluate the ability of TRCs to generate three different types of bone: long bone, jaw bone and spine. Trials involving multiple centers in both the U.S. and Europe are actively evaluating TRCs in the repair of severe non-union fractures, where preliminary results have demonstrated both safety and bone growth success. A trial for the regeneration of spine bone (vertebral fusion) has been initiated in the U.S. under a newly approved IND. In addition, the Company is now engaged in a human clinical trial in Germany evaluating the use of its TRCs to treat limb ischemia in diabetic patients through the regeneration of vascular tissue in extremities.

About Tissue Repair Cells

Tissue Repair Cells (TRCs) are Aastrom's proprietary mixture of bone marrow-derived adult stem and progenitor cells produced using patented single- pass perfusion technology in the AastromReplicell(R) System. The clinical procedure begins with the collection of a small sample of bone marrow from the patient's hip in an outpatient setting. TRCs are then produced in the automated AastromReplicell System over a 12-day period. It has been demonstrated in the laboratory that TRCs are able to develop into different types of tissue lineages in response to inductive signals, including blood, bone, cartilage, adipose and vascular tubules. In previous clinical trials, TRCs have been shown to be safe and reliable in regenerating certain normal healthy bone marrow tissues.
.

[setravis]

Some stocks to watch, or take a look at.
BSML
DYX
BKHM
BSQR

PHOX.OB

[wrangler]

• Technology Research Corporation Announces $2.3 Million in Military Orders
Business Wire (Wed 8:00am) 
• TRCI lands another China contract
bizjournals.com (Mon, Dec 19) 
• Technology Research Corporation Announces $1.7 Million in New Orders from Karcher, a Major Sprayer/Washer Manufacturer
Business Wire (Mon, Dec 19) 

[setravis]

Some stocks to watch, or take a look at.
BSML
DYX
BKHM
BSQR

PHOX.OB

BSML....Now she moves.....big time in the pre-market....

BRITESMILE INC (NasdaqSC:BSML) Delayed quote data 

Pre-Market (RT-ECN): 1.44  0.69 (92.00%)

[OneStockMind]

I know EliteG is out of penny stocks but looking at AMEP chart it looks like a potential G-play if it closes above mid 0.6.

[wrangler]

Does anybody know what happened to runforthedoor, hope he or she is OK. Please post if you know and if they are real bad sick or something else maybe we can get David or Ramsburg to post address and we'll send a card.